Ask AI
ProCE Banner Activity

Novel ADC Therapies for R/R DLBCL: Optimizing Patient Safety With Timely AE Recognition and Management

PDF

Download this resource for healthcare professionals with a brief overview of key adverse events associated with antibody-drug conjugates approved for use in patients with relapsed/refractory diffuse large B-cell lymphoma, including dosing considerations, patient and caregiver counseling tips on monitoring for and reporting key adverse events, and strategies for managing key adverse events.

Released: November 17, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from ADC Therapeutics and Pfizer Inc.

ADC Therapeutics

Pfizer, Inc.

Disclosure

Primary Author

Michael R. Bishop, MD: consultant/advisor/speaker: Bristol Myers Squibb, Chimeric Therapeutics, CRISPR Therapeutic, Galapagos, Incyte, In8bio, Kite/Gilead, Lyell Immunopharm, Novartis.